Logo image of RKDA

ARCADIA BIOSCIENCES INC (RKDA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RKDA - US0390143032 - Common Stock

3.64 USD
-0.01 (-0.27%)
Last: 12/5/2025, 8:00:01 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to RKDA. RKDA was compared to 86 industry peers in the Food Products industry. No worries on liquidiy or solvency for RKDA as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, RKDA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year RKDA has reported negative net income.
RKDA had a negative operating cash flow in the past year.
In the past 5 years RKDA always reported negative net income.
In the past 5 years RKDA always reported negative operating cash flow.
RKDA Yearly Net Income VS EBIT VS OCF VS FCFRKDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of RKDA (-59.03%) is worse than 88.37% of its industry peers.
RKDA has a worse Return On Equity (-93.09%) than 80.23% of its industry peers.
Industry RankSector Rank
ROA -59.03%
ROE -93.09%
ROIC N/A
ROA(3y)-58.73%
ROA(5y)-43.88%
ROE(3y)-98.37%
ROE(5y)-71.81%
ROIC(3y)N/A
ROIC(5y)N/A
RKDA Yearly ROA, ROE, ROICRKDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

RKDA has a Gross Margin of 37.81%. This is amongst the best in the industry. RKDA outperforms 87.21% of its industry peers.
RKDA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RKDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.63%
GM growth 5Y13.12%
RKDA Yearly Profit, Operating, Gross MarginsRKDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

7

2. Health

2.1 Basic Checks

RKDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
RKDA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RKDA has more shares outstanding
RKDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RKDA Yearly Shares OutstandingRKDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
RKDA Yearly Total Debt VS Total AssetsRKDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

RKDA has an Altman-Z score of -44.83. This is a bad value and indicates that RKDA is not financially healthy and even has some risk of bankruptcy.
RKDA has a worse Altman-Z score (-44.83) than 94.19% of its industry peers.
There is no outstanding debt for RKDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -44.83
ROIC/WACCN/A
WACC8.78%
RKDA Yearly LT Debt VS Equity VS FCFRKDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

RKDA has a Current Ratio of 3.67. This indicates that RKDA is financially healthy and has no problem in meeting its short term obligations.
RKDA has a Current ratio of 3.67. This is amongst the best in the industry. RKDA outperforms 89.53% of its industry peers.
RKDA has a Quick Ratio of 3.03. This indicates that RKDA is financially healthy and has no problem in meeting its short term obligations.
RKDA has a better Quick ratio (3.03) than 93.02% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.03
RKDA Yearly Current Assets VS Current LiabilitesRKDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

6

3. Growth

3.1 Past

RKDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.43%, which is quite impressive.
RKDA shows a small growth in Revenue. In the last year, the Revenue has grown by 3.46%.
Measured over the past years, RKDA shows a very strong growth in Revenue. The Revenue has been growing by 33.95% on average per year.
EPS 1Y (TTM)90.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%152.54%
Revenue 1Y (TTM)3.46%
Revenue growth 3Y-9.38%
Revenue growth 5Y33.95%
Sales Q2Q%-15.29%

3.2 Future

RKDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.39% yearly.
The Revenue is expected to grow by 24.10% on average over the next years. This is a very strong growth
EPS Next Y49.49%
EPS Next 2Y23.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20%
Revenue Next 2Y24.1%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RKDA Yearly Revenue VS EstimatesRKDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
RKDA Yearly EPS VS EstimatesRKDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100 -200 -300

1

4. Valuation

4.1 Price/Earnings Ratio

RKDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RKDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RKDA Price Earnings VS Forward Price EarningsRKDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RKDA Per share dataRKDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

RKDA's earnings are expected to grow with 23.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.39%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

RKDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ARCADIA BIOSCIENCES INC

NASDAQ:RKDA (12/5/2025, 8:00:01 PM)

3.64

-0.01 (-0.27%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)11-07 2025-11-07/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners4.77%
Inst Owner Change10.53%
Ins Owners0.26%
Ins Owner Change0%
Market Cap4.99M
Revenue(TTM)5.17M
Net Income(TTM)-5.07M
Analysts82.86
Price Target12.24 (236.26%)
Short Float %6.98%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)157.52%
Min EPS beat(2)102.48%
Max EPS beat(2)212.56%
EPS beat(4)3
Avg EPS beat(4)93.94%
Min EPS beat(4)-229.37%
Max EPS beat(4)290.08%
EPS beat(8)5
Avg EPS beat(8)38.49%
EPS beat(12)8
Avg EPS beat(12)30.28%
EPS beat(16)12
Avg EPS beat(16)30.8%
Revenue beat(2)0
Avg Revenue beat(2)-21.83%
Min Revenue beat(2)-32.82%
Max Revenue beat(2)-10.85%
Revenue beat(4)0
Avg Revenue beat(4)-13.45%
Min Revenue beat(4)-32.82%
Max Revenue beat(4)-0.65%
Revenue beat(8)3
Avg Revenue beat(8)-4.88%
Revenue beat(12)5
Avg Revenue beat(12)-8.99%
Revenue beat(16)6
Avg Revenue beat(16)-8.73%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-4166.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.96
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-2.47
Fwd EYN/A
FCF(TTM)-4.44
FCFYN/A
OCF(TTM)-4.44
OCFYN/A
SpS3.78
BVpS3.97
TBVpS3.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.03%
ROE -93.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.81%
FCFM N/A
ROA(3y)-58.73%
ROA(5y)-43.88%
ROE(3y)-98.37%
ROE(5y)-71.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.63%
GM growth 5Y13.12%
F-Score2
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.67
Quick Ratio 3.03
Altman-Z -44.83
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)10.16%
Cap/Depr(5y)96.24%
Cap/Sales(3y)0.38%
Cap/Sales(5y)9.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%152.54%
EPS Next Y49.49%
EPS Next 2Y23.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.46%
Revenue growth 3Y-9.38%
Revenue growth 5Y33.95%
Sales Q2Q%-15.29%
Revenue Next Year20%
Revenue Next 2Y24.1%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.94%
OCF growth 3YN/A
OCF growth 5YN/A

ARCADIA BIOSCIENCES INC / RKDA FAQ

Can you provide the ChartMill fundamental rating for ARCADIA BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 4 / 10 to RKDA.


Can you provide the valuation status for ARCADIA BIOSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to ARCADIA BIOSCIENCES INC (RKDA). This can be considered as Overvalued.


Can you provide the profitability details for ARCADIA BIOSCIENCES INC?

ARCADIA BIOSCIENCES INC (RKDA) has a profitability rating of 1 / 10.


What is the expected EPS growth for ARCADIA BIOSCIENCES INC (RKDA) stock?

The Earnings per Share (EPS) of ARCADIA BIOSCIENCES INC (RKDA) is expected to grow by 49.49% in the next year.